These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 31733291)

  • 1. Noncoding RNAs as potential mediators of resistance to cancer immunotherapy.
    Vishnubalaji R; Shaath H; Elango R; Alajez NM
    Semin Cancer Biol; 2020 Oct; 65():65-79. PubMed ID: 31733291
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Noncoding RNAs and immune checkpoints-clinical implications as cancer therapeutics.
    Smolle MA; Calin HN; Pichler M; Calin GA
    FEBS J; 2017 Jul; 284(13):1952-1966. PubMed ID: 28132417
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acquired resistance to cancer immunotherapy: Role of tumor-mediated immunosuppression.
    Saleh R; Elkord E
    Semin Cancer Biol; 2020 Oct; 65():13-27. PubMed ID: 31362073
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Noncoding RNAs in cancer immunity: functions, regulatory mechanisms, and clinical application.
    Zhang L; Xu X; Su X
    Mol Cancer; 2020 Mar; 19(1):48. PubMed ID: 32122338
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Noncoding RNAs as novel immunotherapeutic tools against cancer.
    Kaur M; Kaur B; Konar M; Sharma S
    Adv Protein Chem Struct Biol; 2022; 129():135-161. PubMed ID: 35305717
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunomodulatory MicroRNAs in cancer: targeting immune checkpoints and the tumor microenvironment.
    Omar HA; El-Serafi AT; Hersi F; Arafa EA; Zaher DM; Madkour M; Arab HH; Tolba MF
    FEBS J; 2019 Sep; 286(18):3540-3557. PubMed ID: 31306553
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long Non-Coding RNAs in the Tumor Immune Microenvironment: Biological Properties and Therapeutic Potential.
    Pi YN; Qi WC; Xia BR; Lou G; Jin WL
    Front Immunol; 2021; 12():697083. PubMed ID: 34295338
    [TBL] [Abstract][Full Text] [Related]  

  • 8. miRNAs and lncRNAs as Novel Therapeutic Targets to Improve Cancer Immunotherapy.
    Di Martino MT; Riillo C; Scionti F; Grillone K; Polerà N; Caracciolo D; Arbitrio M; Tagliaferri P; Tassone P
    Cancers (Basel); 2021 Mar; 13(7):. PubMed ID: 33808190
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Non-coding RNA and immune-checkpoint inhibitors: friends or foes?
    Shek D; Read SA; Akhuba L; Qiao L; Gao B; Nagrial A; Carlino MS; Ahlenstiel G
    Immunotherapy; 2020 May; 12(7):513-529. PubMed ID: 32378480
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-coding RNA in tumor-infiltrating regulatory T cells formation and associated immunotherapy.
    Ma Y; Xu X; Wang H; Liu Y; Piao H
    Front Immunol; 2023; 14():1228331. PubMed ID: 37671150
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long noncoding RNAs in cancer-immunity cycle.
    Yu WD; Wang H; He QF; Xu Y; Wang XC
    J Cell Physiol; 2018 Sep; 233(9):6518-6523. PubMed ID: 29574911
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overcoming immunotherapeutic resistance by targeting the cancer inflammation cycle.
    Wattenberg MM; Beatty GL
    Semin Cancer Biol; 2020 Oct; 65():38-50. PubMed ID: 31954172
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nanomicelle protects the immune activation effects of Paclitaxel and sensitizes tumors to anti-PD-1 Immunotherapy.
    Yang Q; Shi G; Chen X; Lin Y; Cheng L; Jiang Q; Yan X; Jiang M; Li Y; Zhang H; Wang H; Wang Y; Wang Q; Zhang Y; Liu Y; Su X; Dai L; Tang M; Li J; Zhang L; Qian Z; Yu D; Deng H
    Theranostics; 2020; 10(18):8382-8399. PubMed ID: 32724476
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Noncoding RNAs: the shot callers in tumor immune escape.
    Liu L; Wang Q; Qiu Z; Kang Y; Liu J; Ning S; Yin Y; Pang D; Xu S
    Signal Transduct Target Ther; 2020 Jun; 5(1):102. PubMed ID: 32561709
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Potential Role of circRNA in Tumor Immunity Regulation and Immunotherapy.
    Xu Z; Li P; Fan L; Wu M
    Front Immunol; 2018; 9():9. PubMed ID: 29403493
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exploring potential roles of long non-coding RNAs in cancer immunotherapy: a comprehensive review.
    Arshi A; Mahmoudi E; Raeisi F; Dehghan Tezerjani M; Bahramian E; Ahmed Y; Peng C
    Front Immunol; 2024; 15():1446937. PubMed ID: 39257589
    [TBL] [Abstract][Full Text] [Related]  

  • 17. miRNA as a Modulator of Immunotherapy and Immune Response in Melanoma.
    Nguyen MT; Luo YH; Li AL; Tsai JC; Wu KL; Chung PJ; Ma N
    Biomolecules; 2021 Nov; 11(11):. PubMed ID: 34827646
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Noncoding RNAs as an emerging resistance mechanism to immunotherapies in cancer: basic evidence and therapeutic implications.
    Wang M; Yu F; Li P
    Front Immunol; 2023; 14():1268745. PubMed ID: 37767098
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tackling Resistance to Cancer Immunotherapy: What Do We Know?
    Gondhowiardjo SA; Handoko ; Jayalie VF; Apriantoni R; Barata AR; Senoaji F; Utami IJW; Maubere F; Nuryadi E; Giselvania A
    Molecules; 2020 Sep; 25(18):. PubMed ID: 32911646
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunotherapy for triple-negative breast cancer: Existing challenges and exciting prospects.
    Jia H; Truica CI; Wang B; Wang Y; Ren X; Harvey HA; Song J; Yang JM
    Drug Resist Updat; 2017 May; 32():1-15. PubMed ID: 29145974
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.